JP6871637B2 - 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅 - Google Patents

高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅 Download PDF

Info

Publication number
JP6871637B2
JP6871637B2 JP2018523011A JP2018523011A JP6871637B2 JP 6871637 B2 JP6871637 B2 JP 6871637B2 JP 2018523011 A JP2018523011 A JP 2018523011A JP 2018523011 A JP2018523011 A JP 2018523011A JP 6871637 B2 JP6871637 B2 JP 6871637B2
Authority
JP
Japan
Prior art keywords
mscs
cells
small
msc
young
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018523011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537440A5 (enExample
JP2018537440A (ja
Inventor
トラビス ブロック
トラビス ブロック
ミロス マリンコビック
ミロス マリンコビック
シャオ‐ドン チェン
シャオ‐ドン チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2018537440A publication Critical patent/JP2018537440A/ja
Publication of JP2018537440A5 publication Critical patent/JP2018537440A5/ja
Priority to JP2021066352A priority Critical patent/JP7153951B2/ja
Application granted granted Critical
Publication of JP6871637B2 publication Critical patent/JP6871637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
JP2018523011A 2015-11-04 2016-11-04 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅 Active JP6871637B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021066352A JP7153951B2 (ja) 2015-11-04 2021-04-09 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250664P 2015-11-04 2015-11-04
US62/250,664 2015-11-04
PCT/US2016/060624 WO2017079621A1 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021066352A Division JP7153951B2 (ja) 2015-11-04 2021-04-09 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅

Publications (3)

Publication Number Publication Date
JP2018537440A JP2018537440A (ja) 2018-12-20
JP2018537440A5 JP2018537440A5 (enExample) 2019-12-12
JP6871637B2 true JP6871637B2 (ja) 2021-05-12

Family

ID=58662777

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018523011A Active JP6871637B2 (ja) 2015-11-04 2016-11-04 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅
JP2021066352A Active JP7153951B2 (ja) 2015-11-04 2021-04-09 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021066352A Active JP7153951B2 (ja) 2015-11-04 2021-04-09 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅

Country Status (8)

Country Link
US (1) US11802272B2 (enExample)
EP (1) EP3370740A4 (enExample)
JP (2) JP6871637B2 (enExample)
CN (1) CN108601799A (enExample)
AU (1) AU2016349701B2 (enExample)
CA (1) CA3004296A1 (enExample)
HK (1) HK1254739A1 (enExample)
WO (1) WO2017079621A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153386A1 (en) * 2017-11-17 2019-05-23 James R. Musick Stem cell line for treatment of various medical conditions
CN113166722A (zh) 2018-10-03 2021-07-23 斯特姆生物系统有限公司 羊水细胞来源的细胞外基质及其用途
KR102639023B1 (ko) 2019-02-21 2024-02-20 스템바이오시스, 인크. 양수 세포-유래 ecm 상에서 심근세포 성숙을 위한 방법, 세포 구조, 및 약물 화합물의 심장 독성 및 전부정맥 스크리닝을 위한 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807458B2 (en) * 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
EP2535403B1 (en) 2005-12-08 2019-06-19 University Of Louisville Research Foundation, Inc. Very small embryonic-like (VSEL) stem cells and methods of isolating and using the same
US8084023B2 (en) 2007-01-22 2011-12-27 The Board Of Trustees Of The University Of Arkansas Maintenance and propagation of mesenchymal stem cells
CN102333861A (zh) * 2008-09-30 2012-01-25 路易斯维尔大学研究基金会有限公司 用于分离非常小的胚胎样(vsel)干细胞的方法
BRPI0924921A2 (pt) 2009-03-31 2015-07-07 Univ Texas Métodos de isolar células-tronco mesequimais, de promover proliferação das referidas células e de produção de tecidos diferenciados
EP2614145B1 (en) 2010-09-07 2020-12-02 The Board of Regents of The University of Texas System Tissue-specific differentiation matrices and uses thereof
WO2012135838A1 (en) * 2011-04-01 2012-10-04 University Of Louisville Research Foundation, Inc. Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
CA2857545A1 (en) * 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US20170335286A1 (en) 2014-10-30 2017-11-23 Stembiosys, Inc. Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers

Also Published As

Publication number Publication date
HK1254739A1 (zh) 2019-07-26
AU2016349701A1 (en) 2018-05-24
CA3004296A1 (en) 2017-05-11
CN108601799A (zh) 2018-09-28
AU2016349701B2 (en) 2023-10-19
US20180320140A1 (en) 2018-11-08
EP3370740A4 (en) 2019-05-22
US11802272B2 (en) 2023-10-31
EP3370740A1 (en) 2018-09-12
WO2017079621A1 (en) 2017-05-11
JP2018537440A (ja) 2018-12-20
JP7153951B2 (ja) 2022-10-17
JP2021105047A (ja) 2021-07-26

Similar Documents

Publication Publication Date Title
US11434471B2 (en) Stromal stem cells
Wu et al. Age-related decline in the matrix contents and functional properties of human periodontal ligament stem cell sheets
JP4336821B2 (ja) 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導
JP7153951B2 (ja) 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅
ES2914692T3 (es) Células madre adhesivas derivadas de cordón umbilical mejoradas, método de preparación para las mismas, y uso de las mismas
KR20210041578A (ko) 치수 유래 세포의 제조 방법
El‐Jawhari et al. Collagen‐containing scaffolds enhance attachment and proliferation of non‐cultured bone marrow multipotential stromal cells
Weber et al. In vitro fabrication of autologous living tissue‐engineered vascular grafts based on prenatally harvested ovine amniotic fluid‐derived stem cells
US20200270579A1 (en) Method for preparing dental pulp stem cells from cells derived from dental pulp tissue
KR20110095218A (ko) ＰＩ３Ｋ／ＡＫＴ／ＧＳＫ３ 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 ＣＤ４９ｆ
EP4082613A1 (en) Cell group and method for acquiring same
Menè et al. Isolation and propagation of glomerular mesangial cells
GB2601793A (en) Thymic constructs and uses thereof
CN104513806A (zh) 体外软骨细胞的培养方法
Karlsson et al. Human dermal fibroblasts: a potential cell source for endothelialization of vascular grafts
US10400211B1 (en) Cell composition for tissue regeneration
Marimuthu et al. IN VITRO ANALYSIS AND DIFFERENTIAL CHARACTERISATION OF NUCLEUS PULPOSUS DERIVEDMESENCHYMAL STEM CELLS AND ITS ASSOCIATED STEMNESS AND GENE EXPRESSION CHANGES SUBJECTED TO INFLAMMATORY MARKERS IN HYPOXIC AND NORMOXIC CULTURE CONDITION
Dittmer Decellularized Precision Cut Lung Slices as a model to study in vitro lung regeneration
Caprio et al. The Effect of Replacing Fetal Bovine Serum with Platelet Releasate on the Characterization of MSCs
Chopra et al. Lapine CD133+ CD34+ endothelial progenitor cells for musculoskeletal research in preclinical animal trials
Kornicka et al. Research Article The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process
Olkowska et al. Skeletal Muscle Stem Cells as a tool in muscle regenera on
Sheard Screening and improving the safe provision of mesenchymal stem cells in regenerative medicine: an in vitro study
Chen et al. Proliferative effect of platelet-rich fibrin on canine bone marrow-derived stromal cells
Joshi Master of Veterinary

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210409

R150 Certificate of patent or registration of utility model

Ref document number: 6871637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250